AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00112021
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
- First Posted Date
- 2005-05-24
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 456
- Registration Number
- NCT00111540
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- First Posted Date
- 2005-04-20
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT00108823
- Locations
- 🇬🇧
ALTANA Pharma, Cities in the United Kingdom, United Kingdom
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Type 1 Diabetes MellitusType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2005-04-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00108004
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
Phase 3
Completed
- Conditions
- Bipolar I Disorder
- First Posted Date
- 2005-04-08
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 710
- Registration Number
- NCT00107731
- Locations
- 🇬🇧
Research Site, Welwyn Garden City, United Kingdom
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT00107107
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
- First Posted Date
- 2005-02-18
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00103935
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: exenatide/insulin glargineDrug: insulin glargine/exenatide
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT00099619
- Locations
- 🇵🇱
Research Site, Lublin, Poland
PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT00099580
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
- First Posted Date
- 2004-12-14
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 736
- Registration Number
- NCT00099437
- Locations
- 🇻🇪
Research Site, Caracas, Venezuela
© Copyright 2025. All Rights Reserved by MedPath